The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 01, 2018

Filed:

Oct. 02, 2012
Applicant:

Polyphor Ag, Allschwil, CH;

Inventors:

Françoise Jung, Huningue, FR;

Daniel Obrecht, Bättwil, CH;

Ralf Löwe, Arlesheim, CH;

Johann Zimmermann, Auggen, DE;

Guillaume Lemercier, Village-Neuf, CH;

Eric Chevalier, Steinbrunn-le-bas, FR;

Assignee:

POLYPHOR AG, Allschwil, CH;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 14/47 (2006.01); A01N 37/18 (2006.01); A61P 31/04 (2006.01); A61P 23/00 (2006.01); A61P 17/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61K 38/10 (2006.01); A61K 38/12 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C07K 1/00 (2006.01); C07K 7/08 (2006.01); C07K 7/64 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); C07K 7/64 (2013.01);
Abstract

Novel template-fixed β-hairpin peptidomimetics of the general formula (I): cyclo[P-P-P-P-P-P-P-P-P-P-P-P-P-P-T-T] wherein the single elements T or P are α-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property of antagonizing the biological effect of the receptor FPR1. They can be used as medicaments to treat or prevent diseases or conditions in the areas of inflammatory diseases, allergic conditions, immunological disorders, neuroinflammation, neurological disorders, obstructive airway diseases, infectious diseases, ischemic reperfusion injuries and proliferative disorders such as e.g. cancer. These β-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.


Find Patent Forward Citations

Loading…